NCT07602114

Brief Summary

This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study aims to evaluate whether non-invasive Electrical Impedance Tomography (EIT) can reliably assess cerebral blood flow autoregulation in neurocritically ill participants, by comparing EIT-derived parameters with the current gold-standard invasive index PRx. Cerebral blood flow autoregulation helps maintain stable brain perfusion in critically ill neurological patients. Impaired autoregulation raises the risk of secondary brain injury. The current standard evaluation requires invasive intracranial pressure monitoring, which carries risks of infection, bleeding, and tissue damage. EIT is a non-invasive, radiation-free bedside monitoring technique that uses scalp electrodes to measure real-time changes related to cerebral blood flow, with no additional harm to participants. Adult participants admitted to the neurosurgical intensive care unit who require routine invasive intracranial pressure monitoring will be enrolled, with informed consent provided by legal guardians. All participants receive standard clinical care as prescribed by current medical guidelines; no extra experimental treatments, drugs, or invasive procedures are applied for this study. During the study, invasive monitoring data and non-invasive EIT brain monitoring data will be collected simultaneously. Researchers will analyze the correlation and consistency between EIT-derived parameters and the gold-standard index. This study has received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital, Air Force Military Medical University. All participant information is anonymized to protect privacy, and adverse events will be recorded and reported in accordance with regulatory requirements. The results are expected to support a safe, non-invasive monitoring method for cerebral blood flow autoregulation in neurocritical care.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
24mo left

Started May 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 17, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 22, 2026

Completed
8 days until next milestone

Study Start

First participant enrolled

May 30, 2026

Expected
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2028

3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2028

Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

1.8 years

First QC Date

May 17, 2026

Last Update Submit

May 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Correlation and consistency between EIT-derived parameters and pressure reactivity index (PRx) for cerebral blood flow autoregulation assessment

    To evaluate the linear correlation (Pearson correlation coefficient) and agreement (Bland-Altman analysis) between non-invasive EIT-derived parameters and the invasive gold-standard PRx index in assessing cerebral blood flow autoregulation among neurocritically ill patients.

    Throughout the neurosurgical intensive care unit stay of participants

Interventions

Non-invasive real-time cerebral physiological monitoring performed by attaching standard scalp electrodes and collecting continuous cerebral bio-impedance signals via an Electrical Impedance Tomography (EIT) system. This monitoring is conducted synchronously with routine invasive intracranial pressure and arterial blood pressure monitoring in neurocritical care. It is purely an observational measurement procedure without any therapeutic intervention or modification to standard clinical treatment for participants, aiming to derive EIT-based parameters for evaluating cerebral blood flow autoregulation function.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of adult neurocritical care inpatients admitted to the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, the First Affiliated Hospital of Air Force Military Medical University. Eligible participants are patients aged ≥18 years with severe acute cerebrovascular diseases, severe traumatic brain injury and other critical central nervous system disorders who require NICU admission and routine invasive intracranial pressure and mean arterial pressure monitoring, forming a single-center prospective observational cohort with consecutive enrollment.

You may qualify if:

  • Aged ≥18 years old
  • Diagnosed with acute intracerebral hemorrhage, subarachnoid hemorrhage or ischemic stroke, admitted to the Neurosurgical Intensive Care Unit
  • Receiving routine invasive monitoring of intracranial pressure (ICP) and mean arterial pressure (MAP)
  • Written informed consent obtained from the legally authorized representative

You may not qualify if:

  • Severe scalp damage, infection or skull defect affecting electrode placement
  • Craniotomy history with metal implants interfering with EIT signal acquisition Pregnancy
  • Terminal critical illness with estimated survival \<24 hours
  • Severe coagulation dysfunction or confirmed allergy to electrode materials
  • Unavailable for ≥2-hour continuous valid monitoring data collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2026

First Posted

May 22, 2026

Study Start (Estimated)

May 30, 2026

Primary Completion (Estimated)

February 28, 2028

Study Completion (Estimated)

May 30, 2028

Last Updated

May 22, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared with external researchers due to privacy protection and institutional data security regulations. Aggregated statistical results will be published in peer-reviewed journals.